摘要
目的观察阿托伐他汀钙片与介入溶栓术对早期脑梗死患者过氧化物酶体增生物激活受体γ(PPARγ)、同型半胱氨酸(Hcy)的影响。方法将我院神经内科168例脑卒中患者随机分为试验组及对照组,每组84例。对照组给予阿托伐他汀钙片10 mg,每天1次,口服,持续治疗7 d,试验组在对照组基础上给予介入溶栓术治疗。比较2组患者的血清PPARγ、Hcy、脑钠肽(BNP)、血脂、S100B和高迁移率族蛋白B1(HMGB1)水平。结果治疗后,试验组患者高密度脂蛋白胆固醇(HDL-C)和HMGB1水平分别为(1.49±0.41),(9.82±1.65)mmol·L^-1,对照组分别为(1.18±0.29),(7.64±1.48)mmol·L^-1,差异有统计学意义(P<0.05)。试验组患者血清PPARγ、Hcy、BNP、S100B、三酰甘油(TG)、总胆固醇(TC)和低密度脂蛋白胆固醇(LDL-C)水平分别为(12.37±3.41)pg·m L^-1,(14.43±2.39)μmol·L^-1,(153.71±45.11)ng·m L^-1,(21.16±3.93)mmol·L^-1,(1.76±0.28)mmol·L^-1,(3.43±0.95)mmol·L^-1,(2.15±0.32)mmol·L^-1,对照组分别为(18.36±4.85)pg·m L^-1,(19.14±3.16)μmol·L^-1,(243.76±78.59)ng·m L^-1,(33.51±5.45)mmol·L^-1,(2.27±0.36)mmol·L^-1,(4.82±1.17)mmol·L^-1,(3.47±0.52)mmol·L^-1,差异均有统计学意义(均P<0.05)。治疗期间,对照组药物不良反应发生率为2.38%,包括恶心2例;试验组药物不良反应发生率为3.57%,包括乏力1例,恶心2例,2组药物不良反应发生率差异无统计学意义(P>0.05)。结论对早期脑梗死患者应用介入溶栓术联合阿托伐他汀钙片治疗,能尽早溶栓,调节患者血脂水平,减少缺血缺氧对脑组织损伤,改善患者预后。
Objective To explore the effects on the levels of peroxisome proliferation factor activation factorγ(PPARγ),homocysteine(Hcy)in patients with early brain infarction using interventional fibrinolytic therapy combined with atorvastatin calcium tablets.Methods A total of 168 stroke patients in department of neurology in our hospital were randomly divided into treatment group and control group,with 84 cases in each group.Control group was given atorvastatin calcium tablets orally,once a day,10 mg a time,for 7 d.Treatment group was given interventional thrombolysis therapy on the basis of control group.The levels of serum PPARγ,Hcy,brain natriuretic peptide(BNP),blood lipid,S100 B and high mobility group protein B1(HMGB1)were compared between the twogroups.Results After treatment,the levels of high density lipoprotein cholesterol(HDL-C)and HMGB1 in treatment group were(1.49±0.41)and(9.82±1.65)mmol·L^-1,had significant difference with those in control group,which were(1.18±0.29)and(7.64±1.48)mmol·L^-1(P<0.05).The levels of PPARγ,Hcy,BNP,S100 B,triglyceride(TG),total cholesterol(TC)and low density lipoprotein cholesterol(LDL-C)in treatment group were(12.37±3.41)pg·m L^-1,(14.43±2.39)μmol·L^-1,(153.71±45.11)ng·m L^-1,(21.16±3.93)mmol·L^-1,(1.76±0.28)mmol·L^-1,(3.43±0.95)mmol·L^-1,(2.15±0.32)mmol·L^-1,all had significant difference with those in control group,which were(18.36±4.85)pg·m L^-1,(19.14±3.16)μmol·L^-1,(243.76±78.59)ng·m L^-1,(33.51±5.45)mmol·L^-1,(2.27±0.36)mmol·L^-1,(4.82±1.17)mmol·L^-1,(3.47±0.52)mmol·L^-1(all P<0.05).During treatment,the incidence of adverse drug reactions in control group was 2.38%,including 2 cases of nausea;the incidence of adverse drug reactions in treatment group was3.57%,including 1 case of fatigue and 2 cases of nausea.There was no significant difference in the incidence of adverse drug reactions between the two groups(P>0.05).Conclusion Interventional fibrinolytic therapy combined with atorvastatin calcium tablets can dissolve thrombolysis as e
作者
符青
黄丽云
林雪娟
符少娘
王加良
杨晓帆
FU Qing;HUANG Li-yun;LIN Xue-juan;FU Shao-niang;WANG Jia-liang;YANG Xiao-fan(Department of Pharmacy,First Affiliated Hospital of Hainan Medical College,Haikou 570102,Hainan Province,China;Department of Neurology,First Affiliated Hospital of Hainan Medical College,Haikou 570102,Hainan Province,China;Department of Pharmacy,Hongqi Hospital Affiliated to Mudaryiang Medical College,Mudaryiang 157011,Heilongjiang Province,China;Department of Neurology,Hongqi Hospital Affiliated to Mudaryiang Medical College,Mudaryiang 157011,Heilongjiang Province,China)
出处
《中国临床药理学杂志》
CAS
CSCD
北大核心
2019年第22期2782-2785,共4页
The Chinese Journal of Clinical Pharmacology
基金
海南省医药卫生科研基金资助项目(1341000350A2010)
